Louisville Bioscience, Inc. (also doing business as LBIdxâ¢) made a significant breakthrough in the analysis of blood plasma using Differential Scanning Calorimetry (DSC) for Clinical Diagnosis and Life Science applications. The Plasma Thermogram⢠assay is a robust physical test with high assay reproducibility. It is inexpensive, non-invasive, requires only a single drop of blood, and can be performed in less than an hour. Uniquely Positioned to Dramatically Impact Life Sciences and Clinical Diagnostics through its DSC Expertise and Proprietary Plasma Thermogram⢠platformâ DIAGNOSTIC LBIdx⢠has generated compelling clinical data for numerous diseases including autoimmune diseases and various cancers. Remarkably, distinct diseases generate distinctive and characteristic Plasma Thermograms⢠that are significantly different from healthy "normal" individuals. Validation of our clinical data has been confirmed through independent statistical analysis by a world-renowned expert in Chemometrics and Medical data interpretation. Strategic focus and clinical development has been driven by key stakeholder relationships within the scientific, clinical and business communities. LBIdx⢠will utilize strategic partnerships as well as the low-overhead CLIA Laboratory model to rapidly develop and commercialize new diagnostic tests into high-volume sales within our target markets of Autoimmune Disease Differentiation and Oncology Treatment Monitoring. The first commercialized test will be differential diagnosis of Lupus, Multiple Sclerosis, Rheumatoid Arthritis, Scleroderma and Polymyositis - diseases commonly misdiagnosed with one another. Since the Plasma Thermogram⢠is based upon a novel proprietary platform, broader applications including biomarker discovery, drug target identification and screening. LBIdx⢠has developed a proprietary, label-free Molecular Binding Assay using their DSC platform. DSC allows for quick, reliable assessment of binding of compounds to Albumin (HSA), a1âacid glycoprotein (AGP), other major plasma proteins and whole plasma. Use of human, mouse and proteins from other species are a customizable option. Our assay allows for sensitive, robust and reproducible screening of small molecules and protein interactions crucial to drug discov
